quanfu quanfu

Product Center

/
/
/
Obtained Clinical Trial Approval for a Novel First-in-Class Biologic

Obtained Clinical Trial Approval for a Novel First-in-Class Biologic

  • Categories:Industry news
  • Author:
  • Origin:
  • Time of issue:2017-11-11
  • Views:

(Summary description)In 2017, the company used its own patented technology to develop a first-class biological product: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA (now NMPA) for clinical trials.

Obtained Clinical Trial Approval for a Novel First-in-Class Biologic

(Summary description)In 2017, the company used its own patented technology to develop a first-class biological product: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA (now NMPA) for clinical trials.

  • Categories:Industry news
  • Author:
  • Origin:
  • Time of issue:2017-11-11 10:57
  • Views:
Information

In 2017, the company used its own patented technology to develop a first-class biological product: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA (now NMPA) for clinical trials.

Scan the QR code to read on your phone

Relevant information

Got a project? Contact us today !

At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.

Contact

E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Search